First approval for Sanofi-Aventis's Jevtana
This article was originally published in Scrip
Executive Summary
The US FDA has approved Sanofi-Aventis's chemotherapy drug Jevtana (cabazitaxel) injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.